Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Stefano Crippa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7370-1508; OpenAlex author ID A5042149371, A5049501797, A5159737101. Sources: OpenAlex.

Their work

Papers
80 (first author 12, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
188
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 5 papers · 2018: 2 papers · 2019: 4 papers · 2020: 7 papers · 2021: 9 papers · 2022: 3 papers · 2023: 13 papers · 2024: 8 papers · 2025: 10 papers · 2026: 11 papers

Papers 50 of 80

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Metamorphoses in pancreatic cancer precursors: the role of simple mucinous cysts†. Last author DOI 10.1002/path.6493↗
  3. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  4. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  5. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  6. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  7. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  8. An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
  9. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  10. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  11. ASO Author Reflections: Early Disease-Related Mortality After Neoadjuvant Therapy and Radical Resection for Pancreatic Ductal Adenocarcinoma-The Biological Bur… Co-author DOI 10.1245/s10434-026-19400-y↗
  12. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  13. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  14. Reducing the burden of pancreatic cancer by surveilling mucinous cystic neoplasms: are we there yet? Last author DOI 10.1016/j.bpg.2025.101998↗
  15. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Co-author DOI 10.1016/j.dld.2024.05.017↗
  16. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2024.12.005↗
  17. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  18. Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors. Last author DOI 10.1080/14737140.2025.2450235↗
  19. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  20. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  21. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. First author DOI 10.1097/sla.0000000000006920↗
  22. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  23. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  24. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  25. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.02.005↗
  26. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  27. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  28. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". First author DOI 10.1245/s10434-024-15105-2↗
  29. ASO Author Reflections: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: The Challenge of Minimal Residual Disease. First author DOI 10.1245/s10434-024-15175-2↗
  30. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  31. Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system. Co-author DOI 10.1007/s00428-023-03574-x↗
  32. Limited impact of discretization/interpolation parameters on the predictive power of CT radiomic features in a surgical cohort of pancreatic cancer patients. Co-author DOI 10.1007/s11547-023-01649-y↗
  33. Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection. Co-author DOI 10.1007/s11605-023-05848-w↗
  34. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  35. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  36. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. Co-author DOI 10.1016/j.ejso.2023.03.229↗
  37. European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019. Co-author DOI 10.1016/j.pan.2023.09.001↗
  38. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  39. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  40. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  41. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  42. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  43. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  44. Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. First author DOI 10.1016/j.ejso.2022.04.011↗
  45. Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v28.i10.976↗
  46. Low-frequency of RABL3 pathogenetic variants in hereditary and familial pancreatic cancer. First author DOI 10.1016/j.dld.2020.11.024↗
  47. Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.dld.2021.04.027↗
  48. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Co-author DOI 10.1016/j.ejso.2021.01.001↗
  49. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Co-author DOI 10.1016/j.hpb.2021.04.004↗
  50. The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospecti… Co-author DOI 10.1245/s10434-020-09310-y↗

Closest collaborators

The 25 strongest of 188 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 66 shared papers, 2011–2026 · strength 9.53
  2. Giulio Belfiori · 36 shared papers, 2017–2026 · strength 6.23
  3. Stefano Partelli · 33 shared papers, 2011–2026 · strength 4.38
  4. Domenico Tamburrino · 22 shared papers, 2011–2026 · strength 3.45
  5. Michele Reni · 23 shared papers, 2016–2026 · strength 3.43
  6. Giulia Gasparini · 19 shared papers, 2019–2026 · strength 3.28
  7. Marco Schiavo Lena · 15 shared papers, 2019–2026 · strength 2.66
  8. Federico De Stefano · 11 shared papers, 2023–2026 · strength 2.65
  9. Paolo Riccardo Camisa · 8 shared papers, 2024–2026 · strength 2.15
  10. Diego Palumbo · 11 shared papers, 2021–2026 · strength 2.08
  11. Nicolò Pecorelli · 11 shared papers, 2019–2026 · strength 2.07
  12. Giuseppe Malleo · 10 shared papers, 2022–2026 · strength 1.89
  13. Gabriele Capurso · 11 shared papers, 2019–2026 · strength 1.85
  14. Francesco DE COBELLI · 9 shared papers, 2021–2026 · strength 1.67
  15. Roberto Salvia · 10 shared papers, 2013–2026 · strength 1.65
  16. Claudio Doglioni · 12 shared papers, 2017–2025 · strength 1.60
  17. Gabriella Lionetto · 8 shared papers, 2023–2026 · strength 1.54
  18. Paolo Giorgio Arcidiacono · 9 shared papers, 2017–2026 · strength 1.32
  19. Fabio Casciani · 5 shared papers, 2024–2026 · strength 1.01
  20. Claudio Luchini · 5 shared papers, 2023–2026 · strength 0.95
  21. Marina Macchini · 5 shared papers, 2022–2026 · strength 0.90
  22. Gianpaolo Balzano · 8 shared papers, 2016–2026 · strength 0.85
  23. Daniele Campa · 3 shared papers, 2023–2026 · strength 0.83
  24. Giovanni Guarneri · 6 shared papers, 2017–2024 · strength 0.81
  25. Giulia Orsi · 4 shared papers, 2023–2026 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.